S&P 500 7,580.07 −1.82%
Nasdaq 25,437.00 −2.86%
S&P/TSX 35,620.03 −1.74%
Apple 344.63 −1.23%
Nvidia 204.64 −4.22%
Microsoft 521.91 −1.55%
Shopify 220.37 −5.70%
Royal Bank 283.93 −1.49%
CAD/USD 0.7158 +0.11%
CLOSED · 10:50 ET
Market ClerkRecap
Sun Nov 1 · markets closed1 signal on Oct 31129 insider buys this week · $10BCIRO short report next: Nov 15The week ahead

GYRE

GYRE THERAPEUTICS, INC.
NASDAQ · HEALTH CARE · PHARMACEUTICAL PREPARATIONS
4.56
−1.85 −28.86%
USD · close Oct 30
WatchTime Machine

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

Work order
55
WATCH · shorts 55
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $508.5MP/E —DIV YIELD —FCF YIELD -1.20%REV TTM $119.4M +13.5%NET INCOME −$28.2M −558.6%NET CASH $43.3M52W 4.56 – 8.76SEC XBRL · TTM TO Invalid Date

How GYRE rewrote its risk factors

10-K ITEM 1A · FY2024 → FY2025
Text kept
54%
of sentences unchanged
Added
382
new sentences
Dropped
332
sentences removed
Length
+2,073
words, now 48,523

New in FY2025

  • These risks are discussed more fully below. • There is no assurance when or if the Merger will be completed.
  • Any delay in completing the Merger may substantially reduce the potential benefits that we expect to obtain from the Merger. • Our business is significantly dependent on the sales of ETUARY®, one of our marketed products in the PRC, amid a competitive landscape, and there is a possibility that we may not be able to sustain or boost the sales volume, pricing, and profitability of ETUARY®. • There is a risk that our marketed products in the PRC, ETUARY®, Etorel® and Contiva®, along with any other products that we may receive approval for and commercialize in the future, may not attain sufficient market acceptance among physicians, healthcare facilities, pharmacies, patients, third-party payers, and the broader medical community, which is crucial for their commercial viability. • The future of our business and financial outcomes is largely contingent on the progress and success of our product candidates in clinical and preclinical stages, such as ETUARY® for future indications in the PRC, F573 in the PRC, and Hydronidone in the PRC and in additional markets beyond the PRC.
  • If we fail to secure the needed capital at the critical time, we might have to postpone, scale down, or halt some of our development projects, market introduction initiatives, or other operational aspects. • We may fail to win bids to sell our commercialized products, ETUARY®, and any other future products, if approved and commercialized, to PRC public hospitals through the centralized tender process. • The true market potential for our product and product candidates may be less than expected.
  • Failure to secure necessary approvals, or encountering delays in the approval process, will prevent us from marketing our product candidates, such as ETUARY® for future indications in the PRC, F573 in the PRC, and Hydronidone in the PRC and in additional markets beyond the PRC, which may significantly affect our revenue generation. • Should we or our licensors fail to secure, uphold, defend, or extend adequate patent and other intellectual property rights for our products, ETUARY®, Etorel® and Contiva®, which are approved and commercialized by us in the PRC, and any product candidates globally, or if the breadth of these intellectual property rights is insufficient, our ability to effectively compete in our markets could be compromised. • We have established, and may continue to establish, collaborative agreements and strategic partnerships.
  • However, there is no guarantee we will fully achieve the anticipated benefits from these collaborations, alliances, or licensing agreements, and conflicts could emerge with our present or prospective partners. • Clinical drug development involves a lengthy and expensive process and outcomes are uncertain, and we may not successfully complete clinical trials for drugs under development, including ETUARY® for future indications in the PRC, F573 in the PRC, and Hydronidone in the PRC and in additional markets beyond the PRC, or demonstrate the safety and efficacy of our product candidates to the satisfaction of regulatory authorities. • Our ongoing success is reliant on our capacity to retain key executives and to recruit, maintain, and inspire skilled professionals. • If our intangible assets are impaired, our results of operations and financial condition may be adversely affected. • There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations. • The market price of our common stock has been, and may continue to be, volatile. • We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance with regulations related to operating as a public company.
  • Risks Related to the Merger with Cullgen There is no assurance when or if the Merger will be completed.
  • Any delay in completing the Merger may substantially reduce the potential benefits that we expect to obtain from the Merger.
  • Completion of the Merger is subject to the satisfaction or waiver of a number of conditions, as set forth in the Merger Agreement, including (1) approval by the requisite Cullgen stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, and (2) a filing under HSR Act.
  • There can be no assurance that we and Cullgen will be able to satisfy the closing conditions or that closing conditions beyond our or Cullgen’s control will be satisfied or waived.
  • If the conditions are not satisfied or waived, the Merger may not occur or may not be completed within the expected timeframe, and we may materially and adversely lose some or all of the potential benefits that we expect to achieve as a result of the Merger and could result in additional transaction costs or other effects associated with uncertainty about the Merger.
  • Moreover, we have incurred and expect to continue to incur significant expenses related to the Merger, such as legal and accounting fees, some of which must be paid even if the Merger is not completed.
  • We and Cullgen can agree at any time to terminate the Merger Agreement, even if the Cullgen securityholders have already adopted the Merger Agreement and thereby approved the Merger and the other transactions contemplated by the Merger Agreement.
  • We and Cullgen can also terminate the Merger Agreement under other specified circumstances.
  • The issuance, or expected issuance, of our common stock in connection with the Merger could decrease the market price of our common stock.
  • In connection with the Merger and as part of the merger consideration, we expect to issue shares of common stock to Cullgen stockholders.
  • The anticipated issuance of our common stock in the Merger may result in fluctuations in the market price of our common stock, including a stock price decrease.
  • In addition, the perception in the market that the holders of a large number of shares of our common stock may intend to sell shares could reduce the market price of our common stock.
  • The intended benefits of the Merger may not be realized.
  • The Merger poses risks for our ongoing operations, including, among others: • that senior management’s attention may be diverted from the management of our current operations and development of our products; • costs and expenses associated with any undisclosed or potential liabilities; and • unforeseen difficulties may arise in integrating Cullgen’s and our business.
  • As a result of the foregoing, we may be unable to realize the full strategic and financial benefits currently anticipated from the Merger, and we cannot assure you that the Merger will be accretive to us in the near term or at all.
  • Furthermore, if we fail to realize the intended benefits of the Merger, the market price of our common stock could decline to the extent that the market price reflects those benefits.
  • Our stockholders will have experienced substantial dilution of their ownership interests in us without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent we are able to realize only part of the strategic and financial benefits currently anticipated from the Merger.
  • Because the lack of a public market for Cullgen common stock makes it difficult to evaluate the fairness of the Merger, Cullgen stockholders may receive consideration in the Merger that is greater than or less than the fair market value of Cullgen common stock.
  • The outstanding Cullgen common stock is privately held and is not traded in any public market.
  • The lack of a public market makes it extremely difficult to determine the fair market value of Cullgen shares.
  • Since the percentage of our common stock to be issued to Cullgen stockholders was determined based on negotiations between the parties, it is possible that the value of our common stock to be issued in connection with the Merger will be greater than the fair market value of Cullgen shares.
  • Alternatively, it is possible that the value of the shares of our common stock to be issued in connection with the Merger will be less than the fair market value of Cullgen shares.
  • Our directors and officers may have interests in the Merger that are different from, or in addition to, those of our stockholders generally that may influence them to support or approve the Merger.
  • Our officers and directors may have interests in the Merger that are different from, or are in addition to, those of our stockholders generally.
  • Effective upon the Closing, Ying Luo, Ph.D., current President and Chief Executive Officer of Cullgen, is expected to be employed as Chief Executive Officer and President and appointed as a director of Gyre.
  • Each outstanding option to acquire shares of Cullgen common stock held by Cullgen executive officers and directors will be converted into an option to acquire shares of our common stock.
  • In addition, our directors and executive officers also have certain rights to indemnification or to directors’ and officers’ liability insurance that will survive the completion of the Merger.
  • These interests may have influenced our directors and executive officers to support or recommend the proposals presented to our stockholders.
  • The announcement and pendency of the Merger could have an adverse effect on our business, financial condition, results of operations or business prospects.
  • The announcement and pendency of the Merger could disrupt our business in the following ways, among others: • Our current and prospective employees could experience uncertainty about their future roles, and this uncertainty might adversely affect our ability to retain, recruit and motivate key personnel; • the attention of our management may be directed towards the completion of the Merger and other transaction-related considerations and may be diverted from our day-to-day business operations, as applicable, and matters related to the Merger may require commitments of time and resources that could otherwise have been devoted to other opportunities that might have been beneficial to us; • customers, prospective customers, suppliers, collaborators and other third parties with business relationships with us may decide not to renew or may decide to seek to terminate, change or renegotiate their relationships with us as a result of the Merger, whether pursuant to the terms of their existing agreements with us; and • the market price of our common stock may decline to the extent that the current market price reflects a market assumption that the proposed Merger will be completed.
  • Should they occur, any of these matters could adversely affect our business, or harm our financial condition, results of operations or business prospects.
  • During the pendency of the Merger, we may not be able to enter into a business combination with another party and will be subject to contractual limitations on certain actions because of restrictions in the Merger Agreement.
  • Covenants in the Merger Agreement impede our ability to make dispositions or acquisitions or complete other transactions that are not in the ordinary course of business pending completion of the Merger.
  • As a result, if the Merger is not completed, we may be at a disadvantage to our competitors.
  • In addition, while the Merger Agreement is in effect and subject to limited exceptions, each party is prohibited from soliciting, initiating, encouraging or taking actions designed to facilitate any inquiries or the making of any proposal or offer that could lead to the entering into certain extraordinary transactions with any third party, such as a sale of assets, an acquisition, a tender offer, a merger or other business combination outside the ordinary course of business.

and 342 more.

Gone since FY2024

  • These risks are discussed more fully below. • Our business is significantly dependent on the sales of ETUARY®, our marketed product in the PRC, amid a competitive landscape, and there is a possibility that we may not be able to sustain or boost the sales volume, pricing, and profitability of ETUARY. • There is a risk that our marketed product in the PRC, ETUARY, along with any other products that we may commercialize in the future, including nintedanib and avatrombopag, and may receive approval in the future, may not attain sufficient market acceptance among physicians, healthcare facilities, pharmacies, patients, third-party payers, and the broader medical community, which is crucial for their commercial viability. • The future of our business and financial outcomes is largely contingent on the progress and success of our product candidates in clinical and pre-clinical stages, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC.
  • If we fail to secure the needed capital at the critical time, we might have to postpone, scale down, or halt some of our development projects, market introduction initiatives, or other operational aspects. • The true market potential for our product and product candidates may be less than expected.
  • Failure to secure necessary approvals, or encountering delays in the approval process, will prevent us from marketing our product candidates, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, which may significantly affect our revenue generation. • Should we or our licensors fail to secure, uphold, defend, or extend adequate patent and other intellectual property rights for our products, ETUARY, nintedanib and avatrombopag, which are approved in the PRC, and any product candidates globally, or if the breadth of these intellectual property rights is insufficient, our ability to effectively compete in our markets could be compromised. • We have established, and may continue to establish, collaborative agreements and strategic partnerships.
  • However, there is no guarantee we will fully achieve the anticipated benefits from these collaborations, alliances, or licensing agreements, and conflicts could emerge with our present or prospective partners. • Clinical drug development involves a lengthy and expensive process and outcomes are uncertain, and we may not successfully complete clinical trials for drugs under development, including ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC, or demonstrate the safety and efficacy of our product candidates to the satisfaction of regulatory authorities. • Our ongoing success is reliant on our capacity to retain key executives and to recruit, maintain, and inspire skilled professionals. • If our intangible assets are impaired, our results of operations and financial condition may be adversely affected. • Modifications to laws, regulations, and rules by the PRC government could lead to alterations in our operational processes and business approaches. • There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations. • The market price of our common stock has been, and may continue to be, volatile. • We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance with regulations related to operating as a public company.
  • Risks Related to Our Financial Condition and Capital Requirements Our business is significantly dependent on the sales of ETUARY, our marketed product in the PRC, amid a competitive landscape, and there is a possibility that we may not be able to sustain or boost the sales volume, pricing, and profitability of ETUARY.
  • We are a biotechnology company and have only generated revenues from the commercial sale of ETUARY, which is approved in the PRC, and certain generic drugs.
  • We only have one product and certain generic drugs for commercial sale and are still in the early stages of development of our other product candidates.
  • Sales of ETUARY accounted for 99.3% and 98.9% of our total revenue in 2024 and 2023, respectively, and we expect that sales of ETUARY will continue to comprise a substantial portion of our total revenue in the near future.
  • Notably, the IPF drug market in the PRC is characterized by increasingly fierce competition, with several pirfenidone and nintedanib products approved and commercialized, in addition to our products ETUARY and nintedanib, which Gyre Pharmaceuticals acquired the commercial rights to in May 2024.
  • With the increase in the penetration rate of IPF drugs and the expansion of the overall market, including past new market participants, we expect that more market players will join the IPF market, and, consequently, the sales of our product ETUARY may decrease.
  • For details, see “— Business—Our Products and Product Pipeline — ETUARY: National Category 1.1 New Drug for IPF Approved in 2011 — Market Opportunities and Competition ” in this Annual Report.
  • New entrants to the IPF market in the PRC may exert downward pressure on our average selling price of ETUARY, which may negatively impact sales and/or profit of ETUARY.
  • Furthermore, our competitors may apply for and obtain marketing approvals in the PRC, United States or other countries for products with the same intended use as our generic products, ETUARY and product candidates more rapidly than we do.
  • In addition to market competition from generic drugs and other products or therapies indicated for the same disease, many of the factors discussed in this Risk Factors section could adversely affect sales of ETUARY, including but not limited to, pricing pressures caused by government policies and inclusion or removal from the governmental medical insurance coverage, market acceptance among the medical community, disruptions in manufacturing or distribution, issues with product quality or side effects and disputes over intellectual property.
  • Moreover, despite our efforts, we may be unable to develop or acquire new products that would diversify our business and reduce our dependence on ETUARY.
  • The future of our business and financial outcomes is largely contingent on the progress and success of our product candidates in clinical and pre-clinical stages, such as ETUARY for future indications in the PRC, F573 in the PRC, and F351 in the PRC and in additional markets beyond the PRC.
  • Our ability to generate revenue and realize profitability depends on the successful completion of the development of our product candidates, obtaining necessary regulatory approvals, and manufacturing and commercializing our product candidates, which is contingent upon various factors, including: • the clinical development of ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC; • enhancing our commercial manufacturing capabilities; • our ability to attract, hire and retain skilled personnel; • the successful enrollment in, and completion of, clinical trials, as well as completion of pre-clinical studies and favorable safety and efficacy data therefrom; • receipt of regulatory approvals; • the performance by contract research organizations (“CROs”), or other third parties, of their duties to us in a manner that complies with our trial protocols and applicable laws and protects the integrity of the resulting data; • our ability to acquire or in-license other product candidates and technologies; • obtaining, maintaining, protecting and enforcing patent, trade secret and other intellectual property and proprietary protection and regulatory exclusivity, and ensuring we do not infringe, misappropriate or otherwise violate the patent, trade secret or other intellectual property and proprietary rights of third parties; • successfully launching commercial sales, including our plan to commercially launch nintedanib and avatrombopag; • obtaining and/or maintaining favorable governmental and private medical reimbursement; • efficiently and cost-effectively enhancing our marketing platform and distribution capabilities; • competition with other products and product candidates; • continued acceptable safety profile following regulatory approval, including of ETUARY; • creating additional infrastructure to support operations as a public company and our product development and planned future commercialization efforts; and • delays or other issues with any of the above.
  • As a result, we could experience significant delays in or obtaining or not be able to obtain approval for and/or successful commercialization of our product, ETUARY, and product candidates, which would render us unable to achieve our planned milestones and materially harm our drug development prospects.
  • We have only generated revenues from the commercial sale of ETUARY and certain generic drugs in the PRC and will not be able to generate any product revenues in addition to those generated by ETUARY and certain generic drugs until we receive approval to sell our other product candidates from the NMPA, FDA or other regulatory authorities.
  • As we have only generated revenue from commercial sales of ETUARY and certain generic drugs to date and do not expect to generate any revenue from our other product candidates until they obtain regulatory approval, if ever, we will need to raise substantial additional capital in order to fund our future research and development, including any new clinical trials, product development, partnerships with third parties and strategic collaborations.
  • However, we expect to need to raise substantial additional capital to continue the clinical development of ETUARY for future indications, F573, F528, and F230 in the PRC, and F351 in the PRC and potentially additional markets beyond the PRC, and depending on the availability of capital, may need to delay or cease development of some or all of our product candidates.
  • While we expect that the implementation of our strategies and business plans will require us to rely in part on external financing sources, including our ATM Program with Jefferies LLC, our ability to obtain additional capital on commercially reasonable terms is subject to a variety of factors, many of which are outside of our control, including our future financial condition, results of operations and cash flows, the global economic conditions, industry and competitive conditions, interest rates, prevailing conditions in the credit markets and government policies on lending.
  • Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: • the costs and results of preclinical studies or clinical trials of ETUARY, F351, F573, F528 and F230 or other product candidates, and expenses related to potential clinical development of such candidates; • the expenses associated with promoting academic marketing and expanding our sales and distribution network; • the number and characteristics of product candidates that we pursue; • the terms and timing of any future collaboration, licensing or other arrangements that we may establish; • our need and ability to retain key management and hire scientific, technical, business and medical personnel; • the outcome, timing and cost of regulatory approvals; • our efforts to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; • the effect of competing technological and market developments; • the costs and timing associated with manufacturing our products, including ETUARY and generic products and product candidates for which we may receive regulatory approval, and establishing commercial supplies and sales, marketing and distribution capabilities; • market acceptance of any product candidates for which we may receive regulatory approval; • the capital expenditure required to increase our production capacity and to expand and upgrade our facilities; • the costs of continuing to operate our business, including costs associated with being a public company; and • the extent to which we acquire, license or invest in businesses, products or technologies.
  • For details regarding the risks related to the relations between the PRC and the United States, see “— Risks Related to Our Business Operations in the PRC — Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect our business, financial condition and results of operations. ” If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our strategy.
  • We currently have in place an Open Market Sale Agreement SM with Jefferies LLC that permits us, subject to applicable SEC regulations, to issue up to $50.0 million of shares of our common stock in “at the market” transactions at prevailing market prices.
  • Our plan to grow our business through such acquisitions may not materialize as expected.
  • Our high gross margin during the years ended December 31, 2024 and 2023 may not be sustainable.
  • During the years ended December 31, 2024 and 2023, we maintained a high level of gross margin.
  • Our profit margins were 96.3% and 95.9% for the years ended December 31, 2024 and 2023, respectively, due to our mature technology and significant cost reduction due to the scale effect.
  • For example, changes in the competitive landscape of the relevant markets may decrease the average selling prices of ETUARY, which may have a negative effect on our gross margin.
  • Our five largest customers accounted for a substantial amount of our revenue during the years ended December 31, 2024 and 2023, which subjects us to concentration risks.
  • Our five largest customers accounted for a substantial amount of our revenue for the years ended December 31, 2024 and 2023.
  • As of each of December 31, 2024 and 2023, we had certain concentrations of credit risk of 10%.
  • In addition, as of December 31, 2024, 54.3% and 84.9%, and as of December 31, 2023, 50.5% and 85.5%, of our trade receivables were due from our largest customer and our five largest customers, respectively.
  • If any of our major customers stop purchasing ETUARY or substantially reduce order size in the future, whether due to the termination or amendment of our contractual relationship with such customer, or due to any other reason unrelated to us, we may not be able to identify and sell ETUARY to an alternative customer in a timely manner, or at all.
  • As of December 31, 2024 and 2023, our inventories were valued at $6.3 million and $4.3 million, respectively.
  • During the years ended December 31, 2024 and 2023, we did not identify material inventory items requiring impairment provisioning, and we believe that maintaining appropriate levels of inventory helps us meet market demands in a timely manner.
  • We have intangible assets primarily consisting of product development in progress, patents, technological know-how, and computer software, which accounted for a considerable portion of our total assets as of December 31, 2024 and 2023.
  • As of December 31, 2024 and 2023, our trade receivables amounted to $19.6 million and $15.2 million, respectively, which primarily represented the balances due from our distributors.
  • During the years ended December 31, 2024 and 2023, our trade receivables turnover days were 60 days and 50 days, respectively.

and 292 more.

Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2024 ↗, FY2025 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.

Watch GYRE. Know when insiders buy.
One email the day a filing lands. Free.